ArticleClinical cancer research : an official journal of the American Association for Cancer Research2019

The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib.

Laetitia Marzi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.